Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3040% below fair value
$1.73+0.03 (+1.76%)
Close on Nov 13, 2026Market cap $106.60MP/E –Yield –
Voyager Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Voyager Therapeutics's total assets was $177.05M at Sep 30, 2026. For fiscal 2025 it was $252.28M, down 35.8% from the year before. Over ten years it grew 1.0% a year on average. The highest annual figure on record is $393.05M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $252.28M | -35.8% |
| FY2024 | Dec 31, 2024 | $393.05M | +11.9% |
| FY2023 | Dec 31, 2023 | $351.28M | +120.4% |
| FY2022 | Dec 31, 2022 | $159.36M | -17.8% |
| FY2021 | Dec 31, 2021 | $193.86M | -25.9% |
| FY2020 | Dec 31, 2020 | $261.58M | -26.3% |
| FY2019 | Dec 31, 2019 | $354.76M | +100.4% |
| FY2018 | Dec 31, 2018 | $177.03M | -4.0% |
| FY2017 | Dec 31, 2017 | $184.48M | -2.7% |
| FY2016 | Dec 31, 2016 | $189.57M | -17.4% |
| FY2015 | Dec 31, 2015 | $229.46M | +1895.8% |
| FY2014 | Dec 31, 2014 | $11.50M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $177.05M | -38.6% |
| Q2 FY2026 | Jun 30, 2026 | $197.75M | -38.6% |
| Q1 FY2026 | Mar 31, 2026 | $219.33M | -37.9% |
| Q4 FY2025 | Dec 31, 2025 | $252.28M | -35.8% |
| Q3 FY2025 | Sep 30, 2025 | $288.31M | -32.3% |
| Q2 FY2025 | Jun 30, 2025 | $322.10M | -26.2% |
| Q1 FY2025 | Mar 31, 2025 | $353.24M | -24.8% |
| Q4 FY2024 | Dec 31, 2024 | $393.05M | +11.9% |
| Q3 FY2024 | Sep 30, 2024 | $426.04M | +44.6% |
| Q2 FY2024 | Jun 30, 2024 | $436.23M | +38.2% |
| Q1 FY2024 | Mar 31, 2024 | $469.59M | +39.6% |
| Q4 FY2023 | Dec 31, 2023 | $351.28M | +120.4% |
| Q3 FY2023 | Sep 30, 2023 | $294.65M | +61.5% |
| Q2 FY2023 | Jun 30, 2023 | $315.54M | +67.3% |
| Q1 FY2023 | Mar 31, 2023 | $336.29M | +50.0% |
| Q4 FY2022 | Dec 31, 2022 | $159.36M | -17.8% |
| Q3 FY2022 | Sep 30, 2022 | $182.48M | -1.2% |
| Q2 FY2022 | Jun 30, 2022 | $188.61M | -9.6% |
| Q1 FY2022 | Mar 31, 2022 | $224.18M | -5.7% |
| Q4 FY2021 | Dec 31, 2021 | $193.86M | -25.9% |
| Q3 FY2021 | Sep 30, 2021 | $184.77M | -31.5% |
| Q2 FY2021 | Jun 30, 2021 | $208.73M | -29.8% |
| Q1 FY2021 | Mar 31, 2021 | $237.72M | -26.3% |
| Q4 FY2020 | Dec 31, 2020 | $261.58M | -26.3% |
| Q3 FY2020 | Sep 30, 2020 | $269.76M | -28.3% |
| Q2 FY2020 | Jun 30, 2020 | $297.46M | -23.5% |
| Q1 FY2020 | Mar 31, 2020 | $322.61M | -21.6% |
| Q4 FY2019 | Dec 31, 2019 | $354.76M | +100.4% |
| Q3 FY2019 | Sep 30, 2019 | $376.22M | +90.9% |
| Q2 FY2019 | Jun 30, 2019 | $388.59M | +81.0% |
| Q1 FY2019 | Mar 31, 2019 | $411.35M | +75.0% |
| Q4 FY2018 | Dec 31, 2018 | $177.03M | -4.0% |
| Q3 FY2018 | Sep 30, 2018 | $197.06M | +39.8% |
| Q2 FY2018 | Jun 30, 2018 | $214.66M | +35.5% |
| Q1 FY2018 | Mar 31, 2018 | $235.03M | +34.2% |
| Q4 FY2017 | Dec 31, 2017 | $184.48M | -2.7% |
| Q3 FY2017 | Sep 30, 2017 | $140.92M | – |
| Q2 FY2017 | Jun 30, 2017 | $158.41M | – |
| Q1 FY2017 | Mar 31, 2017 | $175.09M | – |
| Q4 FY2016 | Dec 31, 2016 | $189.57M | – |
See a number that looks wrong?